Literature DB >> 23666872

Involvement of carnitine/organic cation transporter OCTN1/SLC22A4 in gastrointestinal absorption of metformin.

Noritaka Nakamichi1, Hiroyo Shima, Satoshi Asano, Takahiro Ishimoto, Tomoko Sugiura, Kazuki Matsubara, Hiroyuki Kusuhara, Yuichi Sugiyama, Yoshimichi Sai, Ken-Ichi Miyamoto, Akira Tsuji, Yukio Kato.   

Abstract

Metformin is a widely used oral anti-diabetic, but the molecular mechanism(s) of its gastrointestinal membrane permeation remains unclear. Here, we examined the role of carnitine/organic cation transporter OCTN1/SLC22A4, which is localized on apical membranes of small intestine in mice and humans, in metformin absorption. The maximum plasma concentration (Cmax ) after oral administration of metformin (50 mg/kg) in octn1 gene knockout mice (octn1 (-/-) ) was higher than that in wild-type mice, with only a minimal difference in terminal half-life, but Cmax in octn1(-/-) mice given a higher dose (175 mg/kg) was lower than that in wild-type mice. Systemic elimination of metformin after intravenous administration was similar in the two strains, suggesting the possible involvement of OCTN1 in the gastrointestinal absorption. OCTN1-mediated uptake of metformin was observed in human embryonic kidney 293 cells transfected with mouse OCTN1 gene, but much lower than the uptake of the typical substrate [(3) H]ergothioneine (ERGO). In particular, the distribution volume for OCTN1-mediated uptake increased markedly and then tended to decrease as the metformin concentration was increased. Efflux of metformin preloaded in intestinal epithelial cell line Caco-2 was inhibited by ERGO. Overall, the present findings suggest that OCTN1 transports metformin and may be involved in its oral absorption in small intestine.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  ADME; drug transport; oral absorption; organic cation transporter; pharmacokinetics; renal excretion

Mesh:

Substances:

Year:  2013        PMID: 23666872     DOI: 10.1002/jps.23595

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  21 in total

1.  Verapamil decreases the glucose-lowering effect of metformin in healthy volunteers.

Authors:  Sung Kweon Cho; Choon Ok Kim; Eun Seok Park; Jae-Yong Chung
Journal:  Br J Clin Pharmacol       Date:  2014-12       Impact factor: 4.335

2.  Selective Inhibition on Organic Cation Transporters by Carvedilol Protects Mice from Cisplatin-Induced Nephrotoxicity.

Authors:  Dong Guo; Hong Yang; Qing Li; Hyo Jung Bae; Obinna Obianom; Sujuan Zeng; Tong Su; James E Polli; Yan Shu
Journal:  Pharm Res       Date:  2018-09-06       Impact factor: 4.200

3.  Interspecies comparison of the functional characteristics of plasma membrane monoamine transporter (PMAT) between human, rat and mouse.

Authors:  Yoshiyuki Shirasaka; Nora Lee; Haichuan Duan; Horace Ho; Joanna Pak; Joanne Wang
Journal:  J Chem Neuroanat       Date:  2016-09-15       Impact factor: 3.052

4.  Letter to the Editor: "Association between metformin medication, genetic variation and prostate cancer risk"-genotyping and patient categorizations, do they matter?

Authors:  Gerard Marshall Raj; Rama Krishnan
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-08-19       Impact factor: 5.554

Review 5.  Metformin--mode of action and clinical implications for diabetes and cancer.

Authors:  Ida Pernicova; Márta Korbonits
Journal:  Nat Rev Endocrinol       Date:  2014-01-07       Impact factor: 43.330

6.  Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study.

Authors:  Tanja Dujic; Kaixin Zhou; Louise A Donnelly; Roger Tavendale; Colin N A Palmer; Ewan R Pearson
Journal:  Diabetes       Date:  2014-12-15       Impact factor: 9.461

7.  Involvement of organic cation transporter 3 (Oct3/Slc22a3) in the bioavailability and pharmacokinetics of antidiabetic metformin in mice.

Authors:  Yoshiyuki Shirasaka; Nora Lee; Weibin Zha; David Wagner; Joanne Wang
Journal:  Drug Metab Pharmacokinet       Date:  2016-04-30       Impact factor: 3.614

8.  The Effect of Famotidine, a MATE1-Selective Inhibitor, on the Pharmacokinetics and Pharmacodynamics of Metformin.

Authors:  Jennifer E Hibma; Arik A Zur; Richard A Castro; Matthias B Wittwer; Ron J Keizer; Sook Wah Yee; Srijib Goswami; Sophie L Stocker; Xuexiang Zhang; Yong Huang; Claire M Brett; Radojka M Savic; Kathleen M Giacomini
Journal:  Clin Pharmacokinet       Date:  2016-06       Impact factor: 6.447

9.  Metformin Is a Substrate and Inhibitor of the Human Thiamine Transporter, THTR-2 (SLC19A3).

Authors:  Xiaomin Liang; Huan-Chieh Chien; Sook Wah Yee; Marilyn M Giacomini; Eugene C Chen; Meiling Piao; Jia Hao; Jolyn Twelves; Eve-Irene Lepist; Adrian S Ray; Kathleen M Giacomini
Journal:  Mol Pharm       Date:  2015-11-16       Impact factor: 4.939

Review 10.  The Hormetic Effect of Metformin: "Less Is More"?

Authors:  Isabella Panfoli; Alessandra Puddu; Nadia Bertola; Silvia Ravera; Davide Maggi
Journal:  Int J Mol Sci       Date:  2021-06-11       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.